TriangleNCT04824794 · OUTCOME
Dose Escalation, Expansion Part A and Expansion Part B: Pre-dose (Trough) Concentrations (Ctrough) of GEN3014
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- GEOMETRIC_MEAN
- Unit
- ug/mL
- Interval / dispersion
- Geometric Coefficient of Variation
- Time frame
- Dose Escalation: Cycle (C) 1 Day (D) 1, C1D8 (RRMM GEN3014 0.2/0.6 mg/kg, R/R AML Dose Escalation), C2D1, Expansion Part A: C1D1, C2D1 (R/R DLBCL Expansion Part A: C1D8 and C2D8) Expansion Part B: C1D1, C1D8, C2D1, C3D1, C7D1, C8D1 (cycle = 28 days)
What was measured
Venous blood samples were collected for analyzing concentrations of GEN3014. For the RRMM Dose Escalation 0.2/0.6 mg/kg arm, the participant underwent intraparticipant dose escalation in Cycle 1, where the participant received 0.2 mg/kg during the first week and 0.6 mg/kg from second week and beyond. Therefore, PK parameters were additionally calculated for Cycle 1 Day 8 dosing in the RRMM Dose Escalation 0.2/0.6 mg/kg arm to account for the change in dosing over Cycle 1 in this arm.
Analysis population: PK Analysis Set=all participants exposed to GEN3014 with 1+ PK sample with a valid bioanalytical result. Overall number of participants analyzed= participants evaluable for the outcome measure. Number analyzed=participants evaluable at specified timepoint.
Groups in this outcome
RRMM Dose Escalation: GEN3014 0.2/0.6 mg/kg
Participants with RRMM received GEN3014 at a dose of 0.2/0.6 mg/kg by IV infusion in 28-day treatment cycles. Intraparticipant dose escalation was performed in this arm (i.e., dose was escalated from 0.2-0.6 mg/kg).
RRMM Dose Escalation: GEN3014 2 mg/kg
Participants with RRMM received GEN3014 at a dose of 2 mg/kg by IV infusion in 28-day treatment cycles.
RRMM Dose Escalation: GEN3014 4 mg/kg
Participants with RRMM received GEN3014 at a dose of 4 mg/kg by IV infusion in 28-day treatment cycles.
RRMM Dose Escalation: GEN3014 8 mg/kg
Participants with RRMM received GEN3014 at a dose of 8 mg/kg by IV infusion in 28-day treatment cycles.
RRMM Dose Escalation: GEN3014 16 mg/kg
Participants with RRMM received GEN3014 at a dose of 16 mg/kg by IV infusion in 28-day treatment cycles.
RRMM Dose Escalation: GEN3014 24 mg/kg
Participants with RRMM received GEN3014 at a dose of 24 mg/kg by IV infusion in 28-day treatment cycles.
R/R AML Dose Escalation: GEN3014 Dose Level 1
Participants with R/R AML received GEN3014 at dose level 1 (low dose) in 28-day treatment cycles.
RRMM Expansion Part A: GEN3014
Participants with anti-CD38 mAb-naive RRMM received GEN3014 IV infusion at a dose of 16 mg/kg in 28-day cycles during Expansion Part A.
R/R DLBCL Expansion Part A: GEN3014
Participants with R/R DLBCL received GEN3014 IV infusion at a dose of 16 mg/kg in 28-day cycles during Expansion Part A.
RRMM Expansion Part B: Daratumumab
Participants with anti-CD38 mAb-naive RRMM received daratumumab at a dose of 1,800 mg by subcutaneous (SC) injection in 28-day treatment cycles.
RRMM Expansion Part B: GEN3014
Participants with anti-CD38 mAb-naive RRMM received GEN3014 IV infusion at a dose of 16 mg/kg in 28-day treatment cycles.
| Group | Source count |
|---|---|
| RRMM Dose Escalation: GEN3014 0.2/0.6 mg/kg | 1 |
| RRMM Dose Escalation: GEN3014 2 mg/kg | 0 |
| RRMM Dose Escalation: GEN3014 4 mg/kg | 2 |
| RRMM Dose Escalation: GEN3014 8 mg/kg | 3 |
| RRMM Dose Escalation: GEN3014 16 mg/kg | 9 |
| RRMM Dose Escalation: GEN3014 24 mg/kg | 5 |
| R/R AML Dose Escalation: GEN3014 Dose Level 1 | 2 |
| RRMM Expansion Part A: GEN3014 | 8 |
| R/R DLBCL Expansion Part A: GEN3014 | 2 |
| RRMM Expansion Part B: Daratumumab | 42 |
| RRMM Expansion Part B: GEN3014 | 40 |
Reported measurements
Cycle 1 Day 1
| Group | Source count |
|---|---|
| RRMM Dose Escalation: GEN3014 0.2/0.6 mg/kg | 0 |
| RRMM Dose Escalation: GEN3014 2 mg/kg | 0 |
| RRMM Dose Escalation: GEN3014 4 mg/kg | 2 |
| RRMM Dose Escalation: GEN3014 8 mg/kg | 3 |
| RRMM Dose Escalation: GEN3014 16 mg/kg | 7 |
| RRMM Dose Escalation: GEN3014 24 mg/kg | 5 |
| R/R AML Dose Escalation: GEN3014 Dose Level 1 | 0 |
| RRMM Expansion Part A: GEN3014 | 8 |
| R/R DLBCL Expansion Part A: GEN3014 | 0 |
| RRMM Expansion Part B: Daratumumab | 42 |
| RRMM Expansion Part B: GEN3014 | 40 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| RRMM Dose Escalation: GEN3014 4 mg/kg | 7.8266 | 118.8997 | Not reported | Not reported | Not reported |
| RRMM Dose Escalation: GEN3014 8 mg/kg | 21.5977 | 61.8541 | Not reported | Not reported | Not reported |
| RRMM Dose Escalation: GEN3014 16 mg/kg | 46.9134 | 46.6923 | Not reported | Not reported | Not reported |
| RRMM Dose Escalation: GEN3014 24 mg/kg | 32.8319 | 47.9974 | Not reported | Not reported | Not reported |
| RRMM Expansion Part A: GEN3014 | 10.9593 | 919.6537 | Not reported | Not reported | Not reported |
| RRMM Expansion Part B: Daratumumab | 0.1000 | 0.0000 | Not reported | Not reported | Not reported |
| RRMM Expansion Part B: GEN3014 | 0.0308 | 152.5985 | Not reported | Not reported | Not reported |
Cycle 1 Day 8
| Group | Source count |
|---|---|
| RRMM Dose Escalation: GEN3014 0.2/0.6 mg/kg | 1 |
| RRMM Dose Escalation: GEN3014 2 mg/kg | 0 |
| RRMM Dose Escalation: GEN3014 4 mg/kg | 0 |
| RRMM Dose Escalation: GEN3014 8 mg/kg | 0 |
| RRMM Dose Escalation: GEN3014 16 mg/kg | 0 |
| RRMM Dose Escalation: GEN3014 24 mg/kg | 0 |
| R/R AML Dose Escalation: GEN3014 Dose Level 1 | 2 |
| RRMM Expansion Part A: GEN3014 | 0 |
| R/R DLBCL Expansion Part A: GEN3014 | 2 |
| RRMM Expansion Part B: Daratumumab | 42 |
| RRMM Expansion Part B: GEN3014 | 36 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| RRMM Dose Escalation: GEN3014 0.2/0.6 mg/kg | 0.1740 | Not reported | Not reported | Not reported | Not reported |
| R/R AML Dose Escalation: GEN3014 Dose Level 1 | 1.9742 | 2031.9082 | Not reported | Not reported | Not reported |
| R/R DLBCL Expansion Part A: GEN3014 | 47.9468 | 27.9291 | Not reported | Not reported | Not reported |
| RRMM Expansion Part B: Daratumumab | 141.1761 | 48.3833 | Not reported | Not reported | Not reported |
| RRMM Expansion Part B: GEN3014 | 11.6922 | 726.2018 | Not reported | Not reported | Not reported |
Cycle 2 Day 1
| Group | Source count |
|---|---|
| RRMM Dose Escalation: GEN3014 0.2/0.6 mg/kg | 1 |
| RRMM Dose Escalation: GEN3014 2 mg/kg | 0 |
| RRMM Dose Escalation: GEN3014 4 mg/kg | 2 |
| RRMM Dose Escalation: GEN3014 8 mg/kg | 3 |
| RRMM Dose Escalation: GEN3014 16 mg/kg | 9 |
| RRMM Dose Escalation: GEN3014 24 mg/kg | 2 |
| R/R AML Dose Escalation: GEN3014 Dose Level 1 | 0 |
| RRMM Expansion Part A: GEN3014 | 7 |
| R/R DLBCL Expansion Part A: GEN3014 | 0 |
| RRMM Expansion Part B: Daratumumab | 40 |
| RRMM Expansion Part B: GEN3014 | 35 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| RRMM Dose Escalation: GEN3014 0.2/0.6 mg/kg | 0.3480 | Not reported | Not reported | Not reported | Not reported |
| RRMM Dose Escalation: GEN3014 4 mg/kg | 24.0271 | 6.1841 | Not reported | Not reported | Not reported |
| RRMM Dose Escalation: GEN3014 8 mg/kg | 37.3137 | 52.2777 | Not reported | Not reported | Not reported |
| RRMM Dose Escalation: GEN3014 16 mg/kg | 62.8334 | 82.1993 | Not reported | Not reported | Not reported |
| RRMM Dose Escalation: GEN3014 24 mg/kg | 22.3508 | 342.0062 | Not reported | Not reported | Not reported |
| RRMM Expansion Part A: GEN3014 | 35.2277 | 96.6703 | Not reported | Not reported | Not reported |
| RRMM Expansion Part B: Daratumumab | 456.8003 | 44.9599 | Not reported | Not reported | Not reported |
| RRMM Expansion Part B: GEN3014 | 12.9916 | 1603.8261 | Not reported | Not reported | Not reported |
Cycle 3 Day 1
| Group | Source count |
|---|---|
| RRMM Dose Escalation: GEN3014 0.2/0.6 mg/kg | 0 |
| RRMM Dose Escalation: GEN3014 2 mg/kg | 0 |
| RRMM Dose Escalation: GEN3014 4 mg/kg | 0 |
| RRMM Dose Escalation: GEN3014 8 mg/kg | 0 |
| RRMM Dose Escalation: GEN3014 16 mg/kg | 0 |
| RRMM Dose Escalation: GEN3014 24 mg/kg | 0 |
| R/R AML Dose Escalation: GEN3014 Dose Level 1 | 0 |
| RRMM Expansion Part A: GEN3014 | 0 |
| R/R DLBCL Expansion Part A: GEN3014 | 0 |
| RRMM Expansion Part B: Daratumumab | 37 |
| RRMM Expansion Part B: GEN3014 | 32 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| RRMM Expansion Part B: Daratumumab | 639.6531 | 61.6900 | Not reported | Not reported | Not reported |
| RRMM Expansion Part B: GEN3014 | 22.1846 | 313.1853 | Not reported | Not reported | Not reported |
Cycle 7 Day 1
| Group | Source count |
|---|---|
| RRMM Dose Escalation: GEN3014 0.2/0.6 mg/kg | 0 |
| RRMM Dose Escalation: GEN3014 2 mg/kg | 0 |
| RRMM Dose Escalation: GEN3014 4 mg/kg | 0 |
| RRMM Dose Escalation: GEN3014 8 mg/kg | 0 |
| RRMM Dose Escalation: GEN3014 16 mg/kg | 0 |
| RRMM Dose Escalation: GEN3014 24 mg/kg | 0 |
| R/R AML Dose Escalation: GEN3014 Dose Level 1 | 0 |
| RRMM Expansion Part A: GEN3014 | 0 |
| R/R DLBCL Expansion Part A: GEN3014 | 0 |
| RRMM Expansion Part B: Daratumumab | 9 |
| RRMM Expansion Part B: GEN3014 | 6 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| RRMM Expansion Part B: Daratumumab | 461.9240 | 111.2876 | Not reported | Not reported | Not reported |
| RRMM Expansion Part B: GEN3014 | 8.7627 | 6849.5386 | Not reported | Not reported | Not reported |
Cycle 8 Day 1
| Group | Source count |
|---|---|
| RRMM Dose Escalation: GEN3014 0.2/0.6 mg/kg | 0 |
| RRMM Dose Escalation: GEN3014 2 mg/kg | 0 |
| RRMM Dose Escalation: GEN3014 4 mg/kg | 0 |
| RRMM Dose Escalation: GEN3014 8 mg/kg | 0 |
| RRMM Dose Escalation: GEN3014 16 mg/kg | 0 |
| RRMM Dose Escalation: GEN3014 24 mg/kg | 0 |
| R/R AML Dose Escalation: GEN3014 Dose Level 1 | 0 |
| RRMM Expansion Part A: GEN3014 | 0 |
| R/R DLBCL Expansion Part A: GEN3014 | 0 |
| RRMM Expansion Part B: Daratumumab | 7 |
| RRMM Expansion Part B: GEN3014 | 5 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| RRMM Expansion Part B: Daratumumab | 421.3880 | 155.1497 | Not reported | Not reported | Not reported |
| RRMM Expansion Part B: GEN3014 | 1.3497 | 1720.9012 | Not reported | Not reported | Not reported |
Cycle 2 Day 8
| Group | Source count |
|---|---|
| RRMM Dose Escalation: GEN3014 0.2/0.6 mg/kg | 0 |
| RRMM Dose Escalation: GEN3014 2 mg/kg | 0 |
| RRMM Dose Escalation: GEN3014 4 mg/kg | 0 |
| RRMM Dose Escalation: GEN3014 8 mg/kg | 0 |
| RRMM Dose Escalation: GEN3014 16 mg/kg | 0 |
| RRMM Dose Escalation: GEN3014 24 mg/kg | 0 |
| R/R AML Dose Escalation: GEN3014 Dose Level 1 | 0 |
| RRMM Expansion Part A: GEN3014 | 0 |
| R/R DLBCL Expansion Part A: GEN3014 | 1 |
| RRMM Expansion Part B: Daratumumab | 0 |
| RRMM Expansion Part B: GEN3014 | 0 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| R/R DLBCL Expansion Part A: GEN3014 | 82.4000 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG002
- spread
- 118.8997
- value
- 7.8266
- group Id
- OG003
- spread
- 61.8541
- value
- 21.5977
- group Id
- OG004
- spread
- 46.6923
- value
- 46.9134
- group Id
- OG005
- spread
- 47.9974
- value
- 32.8319
- group Id
- OG007
- spread
- 919.6537
- value
- 10.9593
- group Id
- OG009
- spread
- 0.0000
- value
- 0.1000
- group Id
- OG010
- spread
- 152.5985
- value
- 0.0308
- denoms
- counts
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 2
- group Id
- OG003
- value
- 3
- group Id
- OG004
- value
- 7
- group Id
- OG005
- value
- 5
- group Id
- OG006
- value
- 0
- group Id
- OG007
- value
- 8
- group Id
- OG008
- value
- 0
- group Id
- OG009
- value
- 42
- group Id
- OG010
- value
- 40
- units
- Participants
- title
- Cycle 1 Day 1
- categories
- measurements
- group Id
- OG000
- value
- 0.1740
- group Id
- OG006
- spread
- 2031.9082
- value
- 1.9742
- group Id
- OG008
- spread
- 27.9291
- value
- 47.9468
- group Id
- OG009
- spread
- 48.3833
- value
- 141.1761
- group Id
- OG010
- spread
- 726.2018
- value
- 11.6922
- denoms
- counts
- group Id
- OG000
- value
- 1
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 0
- group Id
- OG006
- value
- 2
- group Id
- OG007
- value
- 0
- group Id
- OG008
- value
- 2
- group Id
- OG009
- value
- 42
- group Id
- OG010
- value
- 36
- units
- Participants
- title
- Cycle 1 Day 8
- categories
- measurements
- group Id
- OG000
- value
- 0.3480
- group Id
- OG002
- spread
- 6.1841
- value
- 24.0271
- group Id
- OG003
- spread
- 52.2777
- value
- 37.3137
- group Id
- OG004
- spread
- 82.1993
- value
- 62.8334
- group Id
- OG005
- spread
- 342.0062
- value
- 22.3508
- group Id
- OG007
- spread
- 96.6703
- value
- 35.2277
- group Id
- OG009
- spread
- 44.9599
- value
- 456.8003
- group Id
- OG010
- spread
- 1603.8261
- value
- 12.9916
- denoms
- counts
- group Id
- OG000
- value
- 1
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 2
- group Id
- OG003
- value
- 3
- group Id
- OG004
- value
- 9
- group Id
- OG005
- value
- 2
- group Id
- OG006
- value
- 0
- group Id
- OG007
- value
- 7
- group Id
- OG008
- value
- 0
- group Id
- OG009
- value
- 40
- group Id
- OG010
- value
- 35
- units
- Participants
- title
- Cycle 2 Day 1
- categories
- measurements
- group Id
- OG009
- spread
- 61.6900
- value
- 639.6531
- group Id
- OG010
- spread
- 313.1853
- value
- 22.1846
- denoms
- counts
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 0
- group Id
- OG006
- value
- 0
- group Id
- OG007
- value
- 0
- group Id
- OG008
- value
- 0
- group Id
- OG009
- value
- 37
- group Id
- OG010
- value
- 32
- units
- Participants
- title
- Cycle 3 Day 1
- categories
- measurements
- group Id
- OG009
- spread
- 111.2876
- value
- 461.9240
- group Id
- OG010
- spread
- 6849.5386
- value
- 8.7627
- denoms
- counts
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 0
- group Id
- OG006
- value
- 0
- group Id
- OG007
- value
- 0
- group Id
- OG008
- value
- 0
- group Id
- OG009
- value
- 9
- group Id
- OG010
- value
- 6
- units
- Participants
- title
- Cycle 7 Day 1
- categories
- measurements
- group Id
- OG009
- spread
- 155.1497
- value
- 421.3880
- group Id
- OG010
- spread
- 1720.9012
- value
- 1.3497
- denoms
- counts
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 0
- group Id
- OG006
- value
- 0
- group Id
- OG007
- value
- 0
- group Id
- OG008
- value
- 0
- group Id
- OG009
- value
- 7
- group Id
- OG010
- value
- 5
- units
- Participants
- title
- Cycle 8 Day 1
- categories
- measurements
- group Id
- OG008
- value
- 82.4000
- denoms
- counts
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 0
- group Id
- OG006
- value
- 0
- group Id
- OG007
- value
- 0
- group Id
- OG008
- value
- 1
- group Id
- OG009
- value
- 0
- group Id
- OG010
- value
- 0
- units
- Participants
- title
- Cycle 2 Day 8
- denoms
- counts
- group Id
- OG000
- value
- 1
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 2
- group Id
- OG003
- value
- 3
- group Id
- OG004
- value
- 9
- group Id
- OG005
- value
- 5
- group Id
- OG006
- value
- 2
- group Id
- OG007
- value
- 8
- group Id
- OG008
- value
- 2
- group Id
- OG009
- value
- 42
- group Id
- OG010
- value
- 40
- units
- Participants
- description
- Venous blood samples were collected for analyzing concentrations of GEN3014. For the RRMM Dose Escalation 0.2/0.6 mg/kg arm, the participant underwent intraparticipant dose escalation in Cycle 1, where the participant received 0.2 mg/kg during the first week and 0.6 mg/kg from second week and beyond. Therefore, PK parameters were additionally calculated for Cycle 1 Day 8 dosing in the RRMM Dose Escalation 0.2/0.6 mg/kg arm to account for the change in dosing over Cycle 1 in this arm.
- dispersion Type
- Geometric Coefficient of Variation
- groups
- description
- Participants with RRMM received GEN3014 at a dose of 0.2/0.6 mg/kg by IV infusion in 28-day treatment cycles. Intraparticipant dose escalation was performed in this arm (i.e., dose was escalated from 0.2-0.6 mg/kg).
- id
- OG000
- title
- RRMM Dose Escalation: GEN3014 0.2/0.6 mg/kg
- description
- Participants with RRMM received GEN3014 at a dose of 2 mg/kg by IV infusion in 28-day treatment cycles.
- id
- OG001
- title
- RRMM Dose Escalation: GEN3014 2 mg/kg
- description
- Participants with RRMM received GEN3014 at a dose of 4 mg/kg by IV infusion in 28-day treatment cycles.
- id
- OG002
- title
- RRMM Dose Escalation: GEN3014 4 mg/kg
- description
- Participants with RRMM received GEN3014 at a dose of 8 mg/kg by IV infusion in 28-day treatment cycles.
- id
- OG003
- title
- RRMM Dose Escalation: GEN3014 8 mg/kg
- description
- Participants with RRMM received GEN3014 at a dose of 16 mg/kg by IV infusion in 28-day treatment cycles.
- id
- OG004
- title
- RRMM Dose Escalation: GEN3014 16 mg/kg
- description
- Participants with RRMM received GEN3014 at a dose of 24 mg/kg by IV infusion in 28-day treatment cycles.
- id
- OG005
- title
- RRMM Dose Escalation: GEN3014 24 mg/kg
- description
- Participants with R/R AML received GEN3014 at dose level 1 (low dose) in 28-day treatment cycles.
- id
- OG006
- title
- R/R AML Dose Escalation: GEN3014 Dose Level 1
- description
- Participants with anti-CD38 mAb-naive RRMM received GEN3014 IV infusion at a dose of 16 mg/kg in 28-day cycles during Expansion Part A.
- id
- OG007
- title
- RRMM Expansion Part A: GEN3014
- description
- Participants with R/R DLBCL received GEN3014 IV infusion at a dose of 16 mg/kg in 28-day cycles during Expansion Part A.
- id
- OG008
- title
- R/R DLBCL Expansion Part A: GEN3014
- description
- Participants with anti-CD38 mAb-naive RRMM received daratumumab at a dose of 1,800 mg by subcutaneous (SC) injection in 28-day treatment cycles.
- id
- OG009
- title
- RRMM Expansion Part B: Daratumumab
- description
- Participants with anti-CD38 mAb-naive RRMM received GEN3014 IV infusion at a dose of 16 mg/kg in 28-day treatment cycles.
- id
- OG010
- title
- RRMM Expansion Part B: GEN3014
- param Type
- GEOMETRIC_MEAN
- population Description
- PK Analysis Set=all participants exposed to GEN3014 with 1+ PK sample with a valid bioanalytical result. Overall number of participants analyzed= participants evaluable for the outcome measure. Number analyzed=participants evaluable at specified timepoint.
- reporting Status
- POSTED
- time Frame
- Dose Escalation: Cycle (C) 1 Day (D) 1, C1D8 (RRMM GEN3014 0.2/0.6 mg/kg, R/R AML Dose Escalation), C2D1, Expansion Part A: C1D1, C2D1 (R/R DLBCL Expansion Part A: C1D8 and C2D8) Expansion Part B: C1D1, C1D8, C2D1, C3D1, C7D1, C8D1 (cycle = 28 days)
- title
- Dose Escalation, Expansion Part A and Expansion Part B: Pre-dose (Trough) Concentrations (Ctrough) of GEN3014
- type
- SECONDARY
- unit Of Measure
- ug/mL
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice